This study describes a novel xenograft-based biomarker discovery platform and proves its usefulness in the discovery of serum markers for prostate cancer. By immunizing immuno-competent mice with serum from nude mice bearing prostate cancer xenografts, an antibody response against xenograft-derived antigens was elicited. By probing protein microarrays with serum from immunized mice, several prostate cancer-derived antigens were identified, of which a subset was successfully retrieved in serum from mice bearing prostate cancer xenografts and prevalidated in human serum samples of prostate cancer patients. Among the discovered and validated proteins were the members of the TAM receptor family (TYRO3, AXL, and MERTK), ACY1, and PSMA1. In conclusion, this novel method allows for the identification of low abundant cancer-derived serum proteins, circumventing dynamic range and host-response issues in standard patient cohort proteomics comparisons.

biomarkers, prostate cancer, protoarray, xenograft
dx.doi.org/10.1021/pr2006473, hdl.handle.net/1765/62555
Journal of Proteome Research
Immunology

Jansen, F.H, Rijswijk, A.L, Teubel, W.J, van Weerden, W.M, Reneman, S, van den Bemd, G.J.C.M, … Jenster, G.W. (2012). Profiling of antibody production against xenograft-released proteins by protein microarrays discovers prostate cancer markers. Journal of Proteome Research, 11(2), 728–735. doi:10.1021/pr2006473